Product Description: Acipimox-d4 is the deuterium labeled Acipimox. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox acutely inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity[1].
Formula: C6H2D4N2O3
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. /[2]Esben Thyssen Vestergaard, et al. Short‐term acipimox treatment is associated with decreased cardiac parasympathetic modulation. Br J Clin Pharmacol. 2017 Dec; 83(12): 2671-2677./[3]Y-L Wang-Fisher, et al. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002 Aug;174(2):267-72./[4]B Ahrén. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice. Acta Physiol Scand. 2001 Feb;171(2):161-7.
CAS Number: 1246816-28-3
Molecular Weight: 158.15
Research Area: Metabolic Disease
Solubility: 10 mM in DMSO
Target: Isotope-Labeled Compounds
English
Deutsch
